Genia Technologies, founded in 2009 and based in Mountain View, CA, is a groundbreaking player in the Biotechnology and Health Care sectors. With its ambition encapsulated in the slogan: "Advancing genomic sequencing to the $100 genome, bringing high-speed, accurate, and sensitive DNA sequencing into everyday life," Genia aims to make genomic sequencing more accessible to the public, moving beyond the laboratory constraints.
The company's proprietary technology employs Biological Nanopores for the sequencing of single DNA molecules, diverging from traditional methods like amplification and optical detection. This innovation promises reduced sequencing costs paired with enhanced speed and sensitivity.
Following its establishment in March 2009, Genia recently finalized its Series A funding with a notable influx from a global biotech firm. The latest financial input of $10.44M in Debt Financing was secured on May 29, 2013. Genia's trajectory suggests strong potential for investment, given its disruptive approach in genomics.
